Merck to Buy Verona Pharma for $10 Billion
Merck to Buy Verona Pharma for $10 Billion

Merck to Buy Verona Pharma for $10 Billion

News summary

Merck has announced an agreement to acquire British biopharmaceutical company Verona Pharma for approximately $10 billion, in an all-cash deal offering $107 per American depositary share—a 23% premium over Verona's last closing price. The acquisition focuses on Ohtuvayre, Verona's inhaled treatment for COPD, which received FDA approval in June 2024 and is the first new inhaled COPD therapy in over two decades. Analysts now predict Ohtuvayre could achieve blockbuster status, with potential peak annual sales exceeding $4 billion. Merck plans to capitalize most of the purchase price as an intangible asset to be amortized over Ohtuvayre's commercial life. The transaction has received unanimous board approval from both companies and is expected to close in the fourth quarter of 2025, pending regulatory and shareholder approvals. This acquisition underscores Merck's strategy to diversify its portfolio as its cancer drug Keytruda faces patent expiration in 2028.

Story Coverage
Bias Distribution
58% Left
Information Sources
daae85f0-2883-42fc-b085-888140adf30d71639883-fbbd-48af-8cc3-393f63e7b2efb5604fbc-eed1-463f-8ea7-72fed5b9d859c9756229-35f8-45f1-944f-b88de21be56e
+8
Left 58%
Center 33%
R
Coverage Details
Total News Sources
16
Left
7
Center
4
Right
1
Unrated
4
Last Updated
22 min ago
Bias Distribution
58% Left
Related News
Daily Index

Negative

25Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related News
Recommended News